Enanta Pharmaceuticals | ENTA - Equity Capital And Reserves


Enanta Pharmaceuticals reported $126.59M in Equity Capital and Reserves for its fiscal quarter ending in December of 2025.





Equity Capital And Reserves Change Date
AbbVie USD -6.66B 3.39B Mar/2026
Amgen USD 9.19B 532M Mar/2026
Anika Therapeutics USD 133.9M 9.56M Mar/2026
Arrowhead Research USD 613.98M 45.56M Mar/2026
AstraZeneca USD 47.33B 1.33B Mar/2026
BioCryst Pharmaceuticals USD -553.84M 434.69M Mar/2026
Biogen USD 18.65B 394.9M Mar/2026
Bristol-Myers Squibb USD 20.07B 1.6B Mar/2026
Enanta Pharmaceuticals USD 126.59M 61.87M Dec/2025
Gilead Sciences USD 23.52B 897M Mar/2026
GlaxoSmithKline GBP 17.42B 1.05B Mar/2026
Halozyme Therapeutics USD 219.64M 170.82M Mar/2026
Heron Therapeutics USD 9.14M 4.15M Mar/2026
Immunic USD 151.23M 157.91M Mar/2026
Incyte USD 5.62B 455.37M Mar/2026
Insmed USD 704.85M 34.12M Mar/2026
Ionis Pharmaceuticals USD 491.41M 2.32M Mar/2026
J&J USD 81.19B 358M Mar/2026
Karyopharm Therapeutics USD -292.93M 23.67M Dec/2025
Ligand Pharmaceuticals USD 997.32M 19.89M Mar/2026
Merck USD 45.88B 6.73B Mar/2026
Neurocrine Biosciences USD 3.41B 154.3M Mar/2026
Novartis USD 38.93B 7.2B Mar/2026
Novavax USD -144.76M 17.01M Mar/2026
Pfizer USD 90.1B 3.63B Mar/2026
PTC Therapeutics USD -180.46M 24.85M Mar/2026
Roche Holding CHF 33.8B 758M Dec/2025
Sarepta Therapeutics USD 1.51B 364.48M Mar/2026
Vertex Pharmaceuticals USD 19.36B 696.1M Mar/2026